Table 2.
Comparison of baseline characteristics, treatment, and outcome of risk quartiles as determined by the International IgAN Risk Prediction tool
| Quartiles based on 5-year risk of the outcome | First quartile (n = 24) | Second quartile (n = 24) | Third quartile (n = 23) | Forth quartile (n = 24) | Significance |
|---|---|---|---|---|---|
| 5-Year risk of the outcome (median & range), % | 0.88 (0.3–1.7) | 2.24 (1.8–3.9) | 5.67 (3.9–11.1) | 20.1 (11.1–48.6) | |
| Age at biopsy, years | 34.9±11.6 | 37.0±15.5 | 39.5±14.1 | 34.6±11.7 | p = 0.576 |
| Sex (male:female as %) | 62.5:37.5 | 58:42 | 78:22 | 92:8 | p = 0.038 |
| Follow-up (median as months) | 149.2±62.2 | 155.9±58.1 | 160.3±46.7 | 66.3±57.3 | p < 0.0005 |
| eGFR, mL/min | 94.5±24.0 | 89.6±23.8 | 74.5±24.5 | 51.6±16.9 | p < 0.0005 |
| eGFR-slope 5 years past biopsy, mL/min/year | –0.28±4.36 | –0.74±2.85 | –1.60±3.08 | –4.43±7.62 | p = 0.105 |
| MAP, mm Hg | 95.8±12.4 | 94.6±9.6 | 96.7±11.9 | 108.3±16.8 | p = 0.002 |
| TA-MAP 5 years past biopsy, mm Hg | 93.7±8.6 | 92.6±5.4 | 93.5±6.9 | 99.8±8.78 | p = 0.006 |
| Albuminuria, g/day | 0.20±0.22 | 1.27±1.51 | 1.38±0.77 | 3.41 ±2.47 | p < 0.0005 |
| TA-Albuminuria 5 years past biopsy, g/day | 0.20±0.19 | 0.66±0.63 | 0.73±0.51 | 2.10±2.25 | p < 0.0005 |
| High-degree microhematuria (n = 77), n (%) | 13 (68.4) (n = 19) | 13 (65) (n = 20) | 19 (100) (n = 19) | 16 (84.2) (n = 19) | p = 0.028 |
| History of macrohematuria, n (%) | 15 (62.5) | 9 (37.5) | 11 (47.8) | 4 (16.7) | p = 0.012 |
| BMI (n = 94) | 25.3±5.0 | 26.1±5.0 | 27.4±4.5 (n = 22) | 25.4±4.2 | p = 0.306 |
| Treatment with ACEi or ARB at the time of biopsy, n (%) | 4 (16.7) | 8 (33.3) | 11 (47.8) | 14 (58.3) | p = 0.02 |
| Treatment with ACEi or ARB at the time of at least one follow-up, n (%) | 14 (58.3) | 23 (95.8) | 23 (100) | 21 (87.5) | p < 0.0005 |
| Immunosuppression within 1 year of biopsy, n (%) | 1 (4.2) | 5 (20.8) | 2 (8.7) | 8 (33.3) | p = 0.032 |
| Immunosuppression at any time point during or before the study, n (%) | 2 (8.3) | 7 (29.2) | 5 (21.7) | 11 (45.8) | p = 0.028 |
| Reached the outcome within 5 years, n (%) | 0 (0) | 0 (0) | 0 (0) | 8 (33.3) | p < 0.0005 |
| Reached the outcome, n (%) | 0 (0) | 1 (4.2) | 5 (21.7) | 18 (75) | p < 0.0005 |
| M1 | 4 (16.7) | 8 (33.3) | 6 (26.1) | 14 (58.3) | p = 0.017 |
| E1 | 2 (8.3) | 10 (41.7) | 5 (21.7) | 6 (25) | p = 0.061 |
| S1 | 13 (54.2) | 19 (79.2) | 22 (95.7) | 24 (100) | p < 0.0005 |
| T 2:1:0 | 0:2:22 (0:8.3:91.7) | 0:2:22 (0:8.3:91.7) | 2:10:11 (8.7:43.5:47.8) | 8:13:3 (33.3:54.2:12.5) | p < 0.0005 |
Continuous variables are reported as mean ± standard deviation (SD) unless otherwise stated. When information on a variable is missing from patients, the number in the parenthesis states the number of patients with a valid measurement of the variable in question. Significant p values are highlighted in bold.